These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30718247)

  • 1. Cefepime Pharmacokinetics in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.
    Stitt G; Morris J; Schmees L; Angelo J; Akcan Arikan A
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Al-Shaer MH; Maguigan K; Ashton J; Venugopalan V; Droege ME; Philpott CD; Droege CA; Healy DP; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0161121. PubMed ID: 34662194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystatin C Outperforms Creatinine in Predicting Cefepime Clearance in Pediatric Stem Cell Transplant Recipients.
    Hambrick HR; Fei L; Pavia K; Kaplan J; Mizuno T; Tang P; Schuler E; Benoit S; Girdwood ST
    Transplant Cell Ther; 2024 Jun; 30(6):614.e1-614.e11. PubMed ID: 38522579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).
    Kois AK; Gluck JA; Nicolau DP; Kuti JL
    Int J Antimicrob Agents; 2022 Jul; 60(1):106603. PubMed ID: 35577257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Corley A; Diehl A; Jakob SM; Levkovich BJ; Pellegrino V; Que YA; Reynolds C; Rudham S; Wallis SC; Welch SA; Zacharias D; Roberts JA; Shekar K; Fraser JF
    Int J Antimicrob Agents; 2021 Dec; 58(6):106466. PubMed ID: 34688834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy.
    Pavia K; Hambrick HR; Paice K; Tang P; Punt N; Kaplan J; Goldstein SL; Vinks AA; Mizuno T; Tang Girdwood S
    J Antimicrob Chemother; 2023 Sep; 78(9):2140-2147. PubMed ID: 37466170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
    J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration.
    Ulldemolins M; Bastida C; Llauradó-Serra M; Csajka C; Rodríguez A; Badia JR; Martín-Loeches I; Soy D
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1169-1180. PubMed ID: 33559708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Population Pharmacokinetic Analysis to Study the Effect of Extracorporeal Membrane Oxygenation on Cefepime Disposition in Children.
    Zuppa AF; Zane NR; Moorthy G; Dalton HJ; Abraham A; Reeder RW; Carcillo JA; Yates AR; Meert KL; Berg RA; Sapru A; Mourani P; Notterman DA; Dean JM; Gastonguay MR;
    Pediatr Crit Care Med; 2019 Jan; 20(1):62-70. PubMed ID: 30431557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy.
    Sember AM; LoFaso ME; Lewis SJ
    J Crit Care; 2022 Jun; 69():154011. PubMed ID: 35202996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting serum concentration of vancomycin in critically ill oliguric pediatric patients receiving continuous venovenous hemodiafiltration.
    Lee B; Kim SJ; Park JD; Park J; Jung AH; Jung SH; Choi YH; Kang HG; Ha IS; Cheong HI
    PLoS One; 2018; 13(6):e0199158. PubMed ID: 29927988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous renal replacement therapy in critically ill children: single-center experience.
    Erkol Tuncer GH; Ekim M; Okulu E; Atasay B; Kendirli T
    Turk J Med Sci; 2021 Feb; 51(1):188-194. PubMed ID: 33172226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy.
    Jang SM; Pai MP; Shaw AR; Mueller BA
    Crit Care Med; 2019 Nov; 47(11):e863-e871. PubMed ID: 31397714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.
    Al-Shaer MH; Neely MN; Liu J; Cherabuddi K; Venugopalan V; Rhodes NJ; Klinker K; Scheetz MH; Peloquin CA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Thy M; Urien S; Bouazza N; Foissac F; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M
    Clin Pharmacokinet; 2022 Nov; 61(11):1609-1621. PubMed ID: 36251162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.
    Broeker A; Wicha SG; Dorn C; Kratzer A; Schleibinger M; Kees F; Heininger A; Kees MG; Häberle H
    Crit Care; 2018 Dec; 22(1):341. PubMed ID: 30558639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and Outcome of Critically Ill Pediatric Cancer and Hematopoietic Stem Cell Transplant Patients Requiring Continuous Renal Replacement Therapy: A Retrospective Nationwide Cohort Study.
    Raymakers-Janssen PAMA; Lilien MR; Tibboel D; Kneyber MCJ; Dijkstra S; van Woensel JBM; Lemson J; Cransberg K; van den Heuvel-Eibrink MM; Wösten-van Asperen RM;
    Crit Care Med; 2019 Nov; 47(11):e893-e901. PubMed ID: 31464768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Pharmacokinetic and Pharmacodynamic Evaluation of Every 8-Hour and 12-Hour Dosing Strategies of Vancomycin and Cefepime in Neurocritically ill Patients.
    Kassel LE; Van Matre ET; Foster CJ; Fish DN; Mueller SW; Sherman DS; Wempe MF; MacLaren R; Neumann RT; Kiser TH
    Pharmacotherapy; 2018 Sep; 38(9):921-934. PubMed ID: 29906310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.